265 results
8-K
VBIVQ
VBI Vaccines Inc
25 Jun 24
VBI Vaccines Announces Results of Annual General Meeting
4:15pm
of their successors and (2) approve the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm until the next annual … .
Proposal 2: Approval of the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company until the next annual
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
25 Jun 24
VBI Vaccines Announces Results of Annual General Meeting
4:15pm
EisnerAmper LLP as VBI’s independent registered public accounting firm until the next annual meeting of shareholders and authorizing the audit committee
8-K
EX-1.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
cause (1) the Company’s auditors (the “Accountants”), or other independent accountants satisfactory to the Manager forthwith to furnish the Manager … that they are independent accountants within the meaning of the Act and the Exchange Act and the respective applicable rules and regulations adopted by the Commission
8-K
EX-5.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
of the Company and of public officials. We have not undertaken any independent investigation to verify the accuracy or completeness of any of the foregoing
424B5
VBIVQ
VBI Vaccines Inc
15 May 24
Prospectus supplement for primary offering
4:16pm
operations in order to continue as a going concern.
In its report dated April 16, 2024, EisnerAmper LLP, our independent registered public accounting firm … loss, stockholders’ equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public
8-K
EX-99.1
wwoo1wz
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
8-K
EX-5.1
8s0p2pl3oj6dhc
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-10.1
h1an4p
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-4.2
8sjk3v 0pgqcz41
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-5.2
1hpou4j6h
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-4.1
oaoznplv
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
fleeoclu3
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
7b9upmyzes7
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
t2u6n p5lz6o49aamzkq
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm